What symptoms of menopause can be improved by Veozah (felzonitant)?

Veozah (felzonitant) is a neurokinin 3 (NK3) receptor antagonist, suitable for the treatment of moderate to severe vasomotor symptoms caused by menopause. Veozah (felzonitant) can improve symptoms such as hot flashes, mood swings, and sleep disorders during menopause, and alleviate moderate to severe vasomotor symptoms caused by menopause.

About Veozah (felzonitant)

It helps relieve some symptoms of menopause by regulating hormone levels in the body, especially estrogen. In menopausal women, fezolinetant treatment did not show any significant trends in measured sex hormones (follicle-stimulating hormone, testosterone, estrogen, and dehydroepiandrosterone sulfate). A transient decrease in luteinizing hormone (LH) levels was observed at peak fezolinetant concentrations.

Veozah (fezonatant) improves menopausal symptoms

1. Hot flashes: This is a very common symptom of menopause, which is characterized by a sudden rise in body temperature, a warm feeling in the face, neck and chest, or a sudden strong feeling of heat and sweating, usually accompanied by sweating and heart palpitations.

2. Mood swings: including anxiety, depression, emotional instability, irritability, irritability, etc.

3. Sleep disorders: such as insomnia, excessive dreams, increased number of wakings at night, etc.

4. Loss of sexual desire: Veozah can help improve the symptoms of loss of sexual desire.

5. Vaginal dryness: This symptom is also very common during menopause. Veozah can help relieve uncomfortable symptoms.

6. Reduced bone density: Veozah can help prevent osteoporosis by slowing down bone loss.

Safety and Safety of Veozah in the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause

Research Background

Neurokinin 3 receptor antagonists are potential non-hormonal therapies for the treatment of vasomotor symptoms in menopausal women. Fezonatan is the first non-hormonal neurokinin 3 receptor antagonist in development for the treatment of vasomotor symptoms caused by menopause.

Purpose of the Study

To understand the safety and effectiveness of filazonatant in the treatment of moderate to severe vasomotor symptoms associated with menopause.

Research Methods

In a randomized, double-blind, placebo-controlled, 12-week phase 3 trial, women aged 40 to 65 years with moderate to severe hot flashes were randomly assigned to placebo (n=175), nonazonatant 30 mg (n=176), or nonazonatant 45 mg (n=176).

Results

Fezonemide 30 mg and 45 mg significantly reduced the frequency of vasomotor symptoms compared with placebo at week 4, and compared with placebo at week 4, 30 mg and 45 mg of fezonemide significantly reduced the severity of vasomotor symptoms. Improvements in the frequency and severity of vasomotor symptoms were observed after 1 week and were maintained over 52 weeks.

During the first 12 weeks, treatment-emergent adverse events occurred in 37% of patients in the 30 mg group, 43% in the 45 mg group, and 45% in the placebo group. These events were generally asymptomatic, transient, and resolved during treatment or after treatment interruption.

Research conclusion

Fezonatant can be used as a non-hormonal therapy for the clinical application of menopausal-related vasomotor symptoms.

Dosage

The recommended dose of Veozah (filazonetant) is 45 mg, taken once daily with or without food. Tablets need to be swallowed whole. Tablets must not be cut, crushed or chewed.

Drug prices and treatment costs

The current reference price of 45 mg x 30 tablets of Fezonetam is about $20,655 per box, and the average price of one tablet is $688.5, which is relatively expensive. Moreover, the drug is not listed in the country and is not included in medical insurance, so patients need to pay for it at their own expense.

It costs a patient $20,655 to take it for one month, $41,310 to take it for two months, and so on. How many months you need to take it depends on your own condition and targeted treatment under the guidance of a doctor.

Purchasing channels

1. Purchase abroad: Patients can go abroad to purchase by themselves or ask relatives and friends to go abroad to purchase. They can go to countries such as the United States where the drug is already on the market.

2. Choose a medical service institution: This drug purchasing channel is more convenient and fast. You can obtain drugs by mailing them.

References:

Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, English M, Franklin C, Lee M, Neal-Perry G. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomized controlled study. Lancet. 2023 Apr 1;401(10382):1091-1102. doi: 10.1016/S0140-6736(23)00085-5. Epub 2023 Mar 13. PMID: 36924778.

Related hot article recommendations: